23rd week of 2018 patent applcation highlights part 8 |
Patent application number | Title | Published |
20180153789 | ORAL COMPOSITION - The present disclosure related to an oral composition, and more particularly, to an oral composition for reducing tooth sensitivity. More specifically, the oral composition contains zinc and a copper salt capable of occluding dental tubules by agglomerating proteins, contributing to the reduction effect of tooth sensitivity, and to maintain this, allows a water soluble or alcohol soluble polymer to coat the dental tubules and be maintained for a long time, thereby solving the main cause of tooth sensitivity, as a result, providing an effect on the prevention or reduction of symptoms of tooth sensitivity in a short time. Furthermore, the oral composition according to the present disclosure contains a copper salt or a zinc salt which reacts with dental tubule fluid to form a protein complex, and contains dicarboxylic acid or its salt which reacts with an inorganic matter such as calcium to form a complex to induce occlusion of dental tubules and dramatically increase the occlusion effect, producing an effect on efficient prevention or reduction of tooth sensitivity symptoms in a short time. In addition, the oral composition according to the present disclosure contains dicarboxylic acid and its salt which forms a calcium complex in the mouth to induce occlusion of dental tubules, and further contains a partially soluble calcium salt and/or phosphate to dramatically increase the occlusion effect of the dental tubules, producing an effect on the efficient prevention or reduction of tooth sensitivity symptoms in a short time. | 2018-06-07 |
20180153790 | COMPOSITIONS AND METHODS FOR TREATING HAIR - Disclosed are hair styling compositions comprising at least two latex polymers chosen from acrylate and polyurethane polymers, wherein at least one latex polymer is a film-forming polymer. Methods of styling the hair are also disclosed. | 2018-06-07 |
20180153791 | COSMETIC AND PERSONAL CARE FORMULAS AND METHODS - Applications of low-viscosity phenyl trimethicones in cosmetic and personal care products, cosmetic and personal care formulas containing low-viscosity phenyl trimethicones with various improved properties over use Phenyl Trimethicone @ 20 cSt or @ 40 cSt, and preparation methods thereof are disclosed. | 2018-06-07 |
20180153792 | A Photo-Protective Personal Care Composition - The invention relates to a photo-protective personal care composition, especially to one that provides enhanced stability of a UVA sunscreen of the dibenzoylmethane class when a UVB sunscreen of the cinnamic acid class is also present. This has been achieved by entrapping the UVA sunscreen in a matrix comprising a specific silica and a specific silicone and combining this with a UVB sunscreen being entrapped in a gel made of a silicone elastomer and a volatile silicone. | 2018-06-07 |
20180153793 | COMPOSITION - A cosmetic composition includes: (i) one or more vegetable butters in an amount of from 5 to 35% by weight of the total composition; (ii) one or more vegetable oils in an amount of from 20 to 50% by weight of the total composition; and (iii) starch in an amount of from 40 to 85% by weight of the total composition. The cosmetic composition is free from preservatives as defined herein. | 2018-06-07 |
20180153794 | SUBLINGUAL FORMATION OF RILUZOLE - Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed. | 2018-06-07 |
20180153795 | LIQUID BUPRENORPHINE FORMULATIONS - The invention provides liquid formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides liquid formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering liquid formulations containing buprenorphine or a combination of buprenorphine and naloxone, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof. | 2018-06-07 |
20180153796 | NANOPARTICLES FOR PHOTODYNAMIC THERAPY, X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF - Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, or in radiotherapy-radiodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent. | 2018-06-07 |
20180153797 | NOVEL PARENTERAL CARBAMAZEPINE FORMULATION - The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration. | 2018-06-07 |
20180153798 | Stable Glucagon Peptide Formulations - There is provided glucagon formulations suitable for preparing coatings on microneedle patches for the transdermal delivery of glucagon. The coated patches may be used for the treatment of low blood sugar in diabetic patients. Also provided are glucagon loaded patches, methods for their preparation, and methods of their use. | 2018-06-07 |
20180153799 | METHOD OF RAPIDLY ACHIEVING THERAPEUTIC CONCENTRATIONS OF TRIPTANS FOR TREATMENT OF MIGRAINES - Compositions, devices and methods employing therapeutic concentrations of a triptan for treatment of migraine are described. Also described are methods and apparatuses for delivery of zolmitriptan for achieving a T | 2018-06-07 |
20180153800 | PERSONAL LUBRICANT PROVIDING SEQUENTIAL MULTISENSORIAL PERCEPTIONS AND ARTICLES INCORPORATING SUCH LUBRICANT - The present disclosure provides lubricant compositions suitable for use on human tissue and effective to provide multiple sensations sequentially and/or in varying intensities. The lubricants can include a lubricating base and at least two different sensorial agents effective to impart different sensations, such as warming, cooling, tingling, refreshing, and numbing. The lubricants particularly can be suitable for use in sexual experiences so that the imparted sensations can increase and/or improve such experiences. The present disclosure further provides condoms incorporating such lubricant compositions. | 2018-06-07 |
20180153801 | ORODISPERSIBLE TABLET CONTAINING ESTETROL - The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit containing at least 100 μg of an estetrol component selected from estetrol, estetrol esters and combinations thereof; wherein the solid dosage unit can be obtained by a process comprising: ⋅providing an aqueous liquid comprising water, estetrol component and optionally one or more other pharmaceutically acceptable ingredients; ⋅mixing 1 part by weight of the aqueous liquid with 0.5-20 parts by weight of the carrier particles to produce wet particles; ⋅removing water from the wet particles to produce loaded particles; ⋅optionally mixing the loaded particles with one or more tabletting excipients; and ⋅forming the loaded particles or the mixture of loaded particles and the one or more tabletting excipients into a solid dosage unit. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration. | 2018-06-07 |
20180153802 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS - The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention. | 2018-06-07 |
20180153803 | CROMOLYN COMPOSITIONS AND METHODS THEREOF - Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and packs and kits comprising cromolyn are described. | 2018-06-07 |
20180153804 | FOAMABLE VEHICLES AND PHARMACEUTICAL COMPOSITIONS COMPRISING APROTIC POLAR SOLVENTS AND USES THEREOF - The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof. | 2018-06-07 |
20180153805 | A Ready-to-use Formulation for Vincristine Sulfate Liposome Injection - Disclosed herein are various compositions comprising neoplastic formulations and their methods of use. | 2018-06-07 |
20180153806 | COMBINATION LIPOSOMAL PHARMACEUTICAL FORMULATIONS - Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer. The cancer can be, for example, a lung cancer, preferably non-small cell lung cancer (NSCLC), colon cancer, breast cancer, or liver cancer, preferably hepatocellular carcinoma (HCC). | 2018-06-07 |
20180153807 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIA INFECTIONS AND LUNG DISEASE - Disclosed are methods of treating | 2018-06-07 |
20180153808 | SURFACE DISPLAY OF ANTIGENS ON GRAM-NEGATIVE OUTER MEMBRANE VESICLES - The present invention relates to vaccine compositions based on Gram-negative outer membrane vesicles displaying antigens of pathogens expressed as part of a fusion protein comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria, and use of such compositions in vaccination. The invention further relates to the fusion lipoproteins comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria and antigens of pathogens fused thereto, DNA constructs and bacterial host cells for expressing these fusion lipoproteins and to methods for producing outer membrane vesicles displaying the fusion lipoproteins. | 2018-06-07 |
20180153809 | POWDER COMPOSITION CONTAINING OILY SUBSTANCE - Provided is a powder composition containing an oily substance, the powder composition having good oxidation stability and excellent compression moldability. The powder composition containing an oily substance contains a powdery calcium silicate-based material, and an oily substance impregnated into the material. In the material, a cumulative pore volume for a pore size of 10 to 70 nm is 1.1 cc/g or more, and a cumulative pore volume for a pore size of 70 to 500 nm is 2.0 cc/g or less. | 2018-06-07 |
20180153810 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 2018-06-07 |
20180153811 | Spray-Dried Blood Products and Methods of Making Same - The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above. | 2018-06-07 |
20180153813 | SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE - The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event. | 2018-06-07 |
20180153816 | SOLID DRUG STORAGE APPARATUS, FORMULATIONS AND METHODS OF USE - Embodiments of the invention provide drug packaging and methods for producing drug packaging which can be sealed at room temperature and/or without the need for elevated temperatures above room temperature. Many embodiments provide drug packaging comprising pierceable tubing having a capsule shape (also referred to herein as a pierceable capsule and/or pierceable drug capsule) containing a solid drug such as a drug pellet and methods for producing pierceable drug capsules which can be sealed at room temperature. Embodiments are particularly useful for the packaging and delivery of drugs used in implantable drug delivery devices as well as packaging of drugs that are easily thermally degraded. | 2018-06-07 |
20180153817 | FORMULATIONS FOR ENHANCED BIOAVAILABILITY OF ORALLY ADMINISTERED POLAR AGENTS - A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided. | 2018-06-07 |
20180153818 | PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS - Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions. | 2018-06-07 |
20180153819 | Nanocapsule utilizing mutant chaperonin complex for system of local drug delivery into cell - An object is to provide a technology that relates to a protein nanocapsule capable of holding a substance to be encapsulated such as a drug and in which the protein nanocapsule can be introduced into a cell using a simple method and the encapsulated substance can reach a target in a cell. | 2018-06-07 |
20180153820 | METHODS OF TREATING PANCREATIC CANCER - Provided herein are methods for the treatment of metastatic pancreatic cancer comprising administration of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein in combination with gemcitabine. | 2018-06-07 |
20180153821 | Treating Vasculature Related Diseases or Disorders Using Nanoparticles - The present invention relates to prevention and/or treatment of diseases or disorders associated with a damaged or leaky vasculature in a subject. The present invention provides for methods, combinations and pharmaceutical compositions for preventing and/or treating a disease or disorder associated with a damaged or leaky vasculature in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, an outer surface comprising a cellular membrane derived from a platelet; and optionally an agent for preventing, treating, diagnosing, or prognosing the disease or disorder and/or monitoring prevention or treatment of the disease or disorder. Exemplary diseases or disorders include hemorrhage (bleeding), cardiovascular diseases or disorders, diseases or disorders associated with narrowing of a blood vessel, tumors or cancers. | 2018-06-07 |
20180153822 | Process of Preparing mRNA-Loaded Lipid Nanoparticles - The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA. | 2018-06-07 |
20180153823 | Composition for the Transdermal Delivery of Fentanyl - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 2018-06-07 |
20180153824 | TREATMENT OF ACUTE COMPLICATIONS OF SICKLE CELL DISEASE - The invention provides pharmaceutical compositions and dosage forms of fluorocarbon nanoemulsions that are useful for treating sickle cell disease and related diseases and conditions, as well as methods of preparation and use thereof. | 2018-06-07 |
20180153825 | HONEY FORTIFIED WITH DIHYDROXYACETONE AND METHODS OF MAKING SAME - A dihydroxyacetone fortified honey composition, including a mixture of honey and dissolved dihydroxyacetone in a preferred honey to dissolved dihydroxyacetone ratio of 0.5 ml-20 ml of dissolved dihydroxyacetone to each kilogram of honey, wherein the mixture has a moisture content of between one and twenty percent, and wherein the mixture contains a preferred amount of methylglyoxal of between 83 milligrams of methylglyoxal per 1.0 kilogram of honey and 1500 milligrams of methylglyoxal per 1.0 kilogram of honey. | 2018-06-07 |
20180153826 | MATERIALS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS - In preferred embodiments, the invention pertains to the treatment of Cystic Fibrosis (CF) using an agonistic of CaSR. In a specific embodiment, the subject invention provides a method of treating CF in a subject by administering to the subject a composition comprising a calcimimetic. The calcimimetic can be administered alone or in combination with a CaSR orthosteric agonist and/or an agent capable of stimulating colonic HCO | 2018-06-07 |
20180153827 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER - Methods and compositions for use in treating, preventing or improving diseases related to the liver in an animal, including but not limited to nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD) or nonalcoholic steatohepatitis (NASH), are described. The compounds of the present invention are gamma-ketoaldehyde scavengers. | 2018-06-07 |
20180153828 | METHODS FOR TREATING CANCER - Disclosed herein are methods of inhibiting tumor growth or producing tumor regression in a subject having a drug-resistant estrogen receptor alpha positive cancer or a mutant estrogen receptor alpha positive cancer. The methods entail administering to the subject a therapeutically effective amount of RAD1901 having the structure: | 2018-06-07 |
20180153829 | TREATING ANDROGEN DEPRIVATION THERAPY INDUCED HOT FLASHES AND BONE LOSS IN MEN USING CIS-CLOMIPHENE - This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis, bone fractures, loss of bone mineral density (BMD), and/or hot flashes in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising cis-clomiphene or a pharmaceutically acceptable salt thereof. | 2018-06-07 |
20180153830 | SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS - Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells. | 2018-06-07 |
20180153831 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF - The invention provides novel compounds having the general formula I: | 2018-06-07 |
20180153832 | AQUEOUS GEL COMPOSITION AND METHODS OF USE - The present invention is directed to an aqueous gel composition containing a local anesthetic, a lubricating agent, and a preservative and methods of treating vulvovaginal pain, such as dyspareunia by topically administering said composition. | 2018-06-07 |
20180153833 | TREATMENT AND DIAGNOSIS OF MELANOMA - The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods. | 2018-06-07 |
20180153834 | TREATMENT OF CONDITIONS RELATED TO SHOCK - Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques. | 2018-06-07 |
20180153835 | COMPOSITIONS OF DICLOFENAC ACID - The present invention provides solid oral pharmaceutical compositions comprising wet milled Diclofenac acid and one or more pharmaceutically acceptable excipients and process for preparation thereof. The present invention particularly relates to solid oral pharmaceutical compositions comprising wet milled diclofenac acid with median particle size of less than 1000 nm. In addition the compositions of present invention have the comparable dissolution profiles with marketed composition of diclofenac acid. Maximum Plasma Concentration (C | 2018-06-07 |
20180153836 | DERMAL THERAPEUTIC SYSTEM WITH HIGH ADHESIVITY - The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac. | 2018-06-07 |
20180153837 | METHODS OF IMPROVING PHYSIOLOGICAL RESPONSES RELATED TO POST-TRAUMATIC STRESS DISORDER THROUGH DIETARY SUPPLEMENTATION - The present invention provides methods of improving physiological responses related to post-traumatic stress disorder, wherein the free amino acid beta-alanine, or a salt or ester thereof, is administered to an individual as a human dietary supplement over a period of time in an amount effective to improve physiological responses related to post-traumatic stress disorder. | 2018-06-07 |
20180153838 | LEVOTHYROXINE LIQUID FORMULATIONS - The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use. | 2018-06-07 |
20180153839 | COMPOSITIONS AND METHODS TO REDUCE PHARMACEUTICAL-INDUCED TOXICITY - Provided herein are compositions and methods to reduce toxicity resulting from pharmaceutical treatment, that can lead to increased risk of developing Parkinson's disease (PD) and/or acceleration of PD-associated deterioration. | 2018-06-07 |
20180153840 | THE COMPOSITIONS OF GLYCEROL AND /OR NON-TOXIC AMINO ACIDS FOR INHIBITING AND DESTROYING BIOFILM, INCLUDING RELATED METHODS - The invention relates to compositions that include non-toxic, non-bonded amino acids, individually or in combination, with or without glycerol and other ingredients, used to prevent and treat disease caused by biofilm producing bacteria, fungi, hybrid, or protozoan microorganisms in animals including humans, and to generally prevent reduce, or destroy biofilms by inhibition of formation and in destruction of said biofilms in various other applications. | 2018-06-07 |
20180153841 | COMPOSITIONS AND METHODS FOR INDUCTION OF REMISSION OF INFLAMMATORY BOWEL DISEASES - The present invention discloses compositions which comprises steviol glycoside, citric acid monohydrate, monosodium glutamate and/or glycine. Furthermore, the invention provides diets, nutraceuticals and nutrition oral rehydration therapy, means and methods useful in treating and inducing of remission of inflammation in IBD patients. | 2018-06-07 |
20180153842 | AMINO ACID SUPPLEMENTATION FOR A HEALTHY MICROBIOTA ECOSYSTEM - A nutritional composition is used to reconstitute an optimal healthy microbiota ecosystem in humans or animals. In particular, an ingestible carrier contains specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. In another aspect, specific amino acids are used to reconstitute an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people. | 2018-06-07 |
20180153843 | ANTI-INFLAMMATORY OMEGA-3 SYNERGISTIC COMBINATIONS - This invention is directed to compositions having synergistic combinations of omega-3 fatty acid such as OMEGA-3 with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation. | 2018-06-07 |
20180153844 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS - The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue. | 2018-06-07 |
20180153845 | PHARMACEUTICAL BEAD FORMULATIONS COMPRISING DIMETHYL FUMARATE - The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included. | 2018-06-07 |
20180153846 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT ON STATIN THERAPY - In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, a method of reducing the risk of a cardiovascular event in a subject on statin therapy having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof. | 2018-06-07 |
20180153847 | TREPROSTINIL PRODRUGS - Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs. | 2018-06-07 |
20180153848 | CABAZITAXEL FAT EMULSION, AND PREPARATION METHOD AND USE THEREOF - Provided in the present invention is a cabazitaxel fat emulsion injection, wherein the cabazitaxel fat emulsion injection contains cabazitaxel, a medium chain triglyceride for injection, and lecithin. Also provided in the present invention are the method for preparing the cabazitaxel fat emulsion injection and the use thereof in preparing a drug for treating prostate cancer. | 2018-06-07 |
20180153849 | MULTI-DRUG COMBINATIONS THAT ACT AS POTENT RADIOSENSITIZERS - Provided is a method of treatment including administering to lung, brain or esophageal cancer cells an effective amount of radiation in conjunction with a micelle composition that includes an effective amount of paclitaxel, and one or both of 17-AAG, and rapamycin, wherein the micelle includes poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA). | 2018-06-07 |
20180153850 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER - Methods and compositions are provided for treatment of cancer, including prostate cancer. In one aspect, the present invention provides a composition comprising a taxane and a drug that reduces efflux of the taxane from a cell. The drug that reduces efflux of the taxane can be an inhibitor of ABCB1 efflux activity. In some cases, the inhibitor of ABCB1 efflux activity is an inhibitor of ABCB1 ATPase activity selected from the group consisting of enzalutamide and bicalutamide. | 2018-06-07 |
20180153851 | MONOTERPENES FOR TREATING RESPIRATORY DISEASES, IN PARTICULAR BRONCHOPULMONARY DISEASES - The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects). | 2018-06-07 |
20180153852 | COMPOSITION FOR PREVENTING AND TREATING MUSCLE DISEASES OR IMPROVING MUSCULAR FUNCTION, CONTAINING MORUSIN, KUWANON G, OR MORI CORTEX RADICIS - The present invention relates to a composition for preventing and treating muscle diseases or improving muscular function, containing, as an active ingredient, at least one selected from the group consisting of morusin, kuwanon G, and a Mori Cortex Radicis extract. The Mori Cortex Radicis extract, morusin, or kuwanon G, according to the present invention, has an effect of remarkably enhancing muscular function by increasing the expression of p-mTOR protein involved in muscular protein synthesis, inhibiting the expression of mRNAs of MuRF-1 and atrogin-1 involved in muscular protein degradation, and increasing the expression of mRNAs of MyoD and myogenin involved in muscular differentiation. In addition, the present invention is a natural product so as to be used safely without side effects, thereby being usable in drugs, food, or cosmetics. | 2018-06-07 |
20180153853 | INHIBITION OF CANCER CELL MOTILITY - Provided herein are compositions and methods for inhibiting cancer cell motility and/or metastasis. In particular embodiments, KBU2046 (or an analog thereof) and one or more additional therapies (e.g., cancer therapies (e.g., hormone therapies and chemotherapies) are provided to inhibit cancer cell motility, inhibit metastasis, and/or treat cancer (e.g., prostate cancer, lung cancer, breast cancer, colon cancer, etc.). | 2018-06-07 |
20180153854 | NON-AROMATIC DIFLUORO ANALOGUES OF RESORCYLIC ACID LACTONES - This disclosure is directed to non-aromatic difluoro analogues of resorcylic acid lactones, pharmaceutical compositions comprising non-aromatic difluoro analogues of resorcylic acid lactones, and methods of treatment comprising non-aromatic difluoro analogues of resorcylic acid lactones. | 2018-06-07 |
20180153855 | SIGMA RECEPTOR-BINDING AGENT - A sigma receptor-binding agent, which comprises an alkyl ether derivative represented by formula [1] or a salt thereof is provided. | 2018-06-07 |
20180153856 | USE OF STATINS FOR PERIODONTAL DISEASE AND BONE REGENERATION - The present invention discloses topical compositions comprising at least one statin as the main active compound for primary prevention or treatment of periodontal disease, for complementing standard treatment of periodontal disease, and for bone regeneration. The topical compositions are formulated for example, but not limited to, as toothpaste, mouthwash, tablets to dissolve in the mouth, elements or devices for intraoral slow-release of statins, dental floss, gel for being applied in dental trays, concentrated gel for irrigation of periodontal pockets, fluid (for example in blisters), powder, powder or liquid for preparing a solution, and gel. The present invention also discloses method for primary prevention or treatment of periodontal disease, for complementing standard treatment of periodontal disease, and for bone regeneration, comprising administering the topical compositions in the different formulations to a subject in need thereof. | 2018-06-07 |
20180153857 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B - Inhibitors of HBV replication of Formula (I) | 2018-06-07 |
20180153858 | METHODS FOR IDENTIFYING AND USING INHIBITORS OF CASEIN KINASE 1 EPSILON ISOFORM FOR INHIBITING THE GROWTH AND/OR PROLIFERATION OF MYC-DRIVEN TUMOR CELLS - In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells. | 2018-06-07 |
20180153859 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE - The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders based on the ApoE4 genotype of human subjects. | 2018-06-07 |
20180153860 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES - The present invention provides indane acetic acid and their derivatives and methods for the treating and/or preventing of cognitive disorders. | 2018-06-07 |
20180153861 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS - The present invention provides a compound of Formula I for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R | 2018-06-07 |
20180153862 | SUBLINGUAL ADMINISTRATION OF RILUZOLE - Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed. | 2018-06-07 |
20180153863 | METHODS OF TREATING SOLID TUMORS USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY - The present invention relates to methods and compositions for the treatment of a solid tumor by administering compositions comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug, e.g., sirolimus or a derivative thereof) and an albumin in combination with compositions comprising a second therapeutic agent. | 2018-06-07 |
20180153864 | COMPOSITION COMPRISING COMBINATION OF RAPAMYCIN AND AN ACTIVATOR OF AMP KINASE AND USE THEREOF FOR TREATING DISEASES - A formulation, especially one that is topically administered, comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. The topical formulation may be a gel, an ointment, a cream or a lotion. The topical formulation may be used to treat any disease associated with inflammation and/or any inflammatory skin disease. | 2018-06-07 |
20180153865 | NEW USE OF INHIBITOR OF CYSTINE-GLUTAMATE TRANSPORTER - The invention surprisingly found that agents that inhibit system x | 2018-06-07 |
20180153866 | TREATMENT OF SUNBURN USING ANALGESICS AND ANTIHISTAMINES - Combination compositions and kits comprising an analgesic and an antihistamine are provided as well as methods of use in treating sunburn. | 2018-06-07 |
20180153867 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT - Methods for treating prostate cancer comprising administering to a subject in need thereof a bromodomain inhibitor concomitantly with a second agent. The second agent may be an androgen receptor antagonist. In some methods, the prostate cancer is castrate-resistant prostate cancer. | 2018-06-07 |
20180153868 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT - Methods for treating breast cancer comprising administering to a subject in need thereof a bromodomain inhibitor concomitantly with a second agent. The second agent may be an aromatase inhibitor, a selective estrogen receptor modulator, or a selective estrogen receptor down-regulator. In some methods, the breast cancer is estrogen-receptor positive breast cancer. | 2018-06-07 |
20180153869 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2018-06-07 |
20180153870 | BIPERIDEN FOR TREATING CANCER - The present invention relates to the use of the compound biperiden as a MALT1 inhibitor in the treatment of a cancerous disease. The invention in particular relates to a combination of biperiden and a phenothiazine for use in the treatment of a cancerous disease. In a further aspect, the present invention is directed to a pharmaceutical composition for the treatment of a cancerous disease which comprises biperiden as a MALT1 inhibitor. Furthermore, a pharmaceutical composition is disclosed which comprises biperiden and at least a phenothiazine. In a further aspect, the invention relates to the use of biperiden in the treatment of a cancerous disease. The invention further provides a kit which comprises a container that includes biperiden and at least one container that includes a phenothiazine compound. | 2018-06-07 |
20180153871 | COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA - The disclosure provides a novel polymorph of Compound (I): | 2018-06-07 |
20180153872 | HETEROARYL CARBONITRILES FOR THE TREATMENT OF DISEASE - The invention relates to pharmaceutical compositions and dosage forms having a piperidine carbonitrile as an active ingredient for the treatment of various diseases and conditions. The preferred compound is a crystalline form of a trifluoromethylphenylalkoxyalkylheteroarylaryl piperidine carbonitrile. Methods of treating diseases and conditions are disclosed as well as processes to make crystalline forms of the above compounds. | 2018-06-07 |
20180153873 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases due to mutations in Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2018-06-07 |
20180153874 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis. | 2018-06-07 |
20180153875 | AQUEOUS DRUG - An aqueous drug in which the chemical decomposition of the compound represented by formula (1) or of a salt thereof is inhibited, and a method for producing said aqueous drug. An aqueous drug provided with: a solution (liquid A) that contains the compound represented by formula (1) or a salt thereof and that has a pH of 5.3 or less; and a dilution liquid (liquid B) that is mixed with the liquid A in order to prepare a solution to be administered. | 2018-06-07 |
20180153876 | CGRP Receptor Antagonists - The disclosures herein relate to novel compounds of formula | 2018-06-07 |
20180153877 | THERAPEUTIC TARGETING OF MYELOPOLIFERATIVE NEOPLASMAS BY DUSP1 INHIBITION - Methods and compositions disclosed herein generally relate to methods, compounds, and compositions for treating myeloproliferative neoplasms (MPNs) or a symptom thereof, comprising administering, to a subject in need thereof, a therapeutically effective amount of a DUSP1 inhibiting compound, or of a pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof. Embodiments of the invention also relate to use of a compound, or pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof, for the preparation of a composition or medicament for the treatment of a myeloproliferative neoplasm (MPN), wherein the compound is an inhibitor of DUSP1. | 2018-06-07 |
20180153878 | ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING THE SAME - An oral solid formulation includes irinotecan or a pharmaceutically acceptable salt thereof as an active ingredient, and an acidifying agent. | 2018-06-07 |
20180153880 | COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME - The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals. | 2018-06-07 |
20180153881 | Dosing Regimens for Fast Onset of Antidepressant Effect - A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone. | 2018-06-07 |
20180153882 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases - The present invention provides a compound of Formula I or Formula II: | 2018-06-07 |
20180153883 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS - Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma. | 2018-06-07 |
20180153884 | COMBINATION COMPOSITIONS FOR IMMUNOTHERAPY - The present invention relates to therapeutic combinations comprising WNT inhibitors and methods for treating cancers using combination therapy. | 2018-06-07 |
20180153885 | PRESERVATIVE FREE OCULAR COMPOSITIONS AND METHODS FOR USING THE SAME FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS - The present invention provides a preservative free ophthalmic formulation. In particular, the ophthalmic formulations of the invention are aqueous formulations comprising nanoemulsion of oil. The present invention also provides a method for treating an eye disorder. In one particular embodiment, the invention provides methods for treating dry eye syndrome using an preservative free formulation comprising a nanoemulsion of oil and alpha 2 adrenergic agonist, pharmaceutically acceptable salt thereof or a mixture thereof. In particular, the alpha 2 adrenergic agonist of the invention has a higher alpha 2A agonist activity compared to alpha 2B agonist activity. This invention also provides a preservative free ophthalmic composition comprising a nanoemulsion of oil, a therapeutically effective amount of an alpha 2 adrenergic agonist, a pharmaceutically acceptable salt thereof or a combination thereof as an active ingredient for treating a dry eye syndrome. | 2018-06-07 |
20180153886 | USE OF TRIMETHAZINE IN PREPARATION OF DRUGS FOR PREVENTING AND TREATING LIVER DISEASES - Disclosed is a use of trimethazine in the preparation of drugs for preventing and treating liver diseases. Trimethazine is capable of inhibiting activation of resting T-cells to activated lymphocytes, reducing release of cytokines, and reducing hepatocyte injury caused by immune system; inhibiting fatty acid metabolism in hepatocytes, and optimizing the energy process in hepatocytes; and maintaining normal function of mitochondrial permeability transition pores, and reducing hepatocyte apoptosis. Trimethazine has the efficacy of maintaining the liver functions, and reducing transminase (comprising glutamic pyruvic transaminase, glutamic oxalacetic transaminase, etc.). | 2018-06-07 |
20180153887 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE - Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): | 2018-06-07 |
20180153888 | COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS - An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination. | 2018-06-07 |
20180153889 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES - Phthalazinediones that function as intracellular redox modulators in the redox therapy of certain stressed cells are provided. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions. | 2018-06-07 |
20180153890 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - The present disclosure provides pharmaceutical compositions comprising micronized Compound A and use thereof. | 2018-06-07 |
20180153891 | ANTIEPILEPTIC DRUGS - The present invention describes novel pharmaceutical compositions and methods for treatment of diseases, disorders, or conditions characterized by recurrent seizures, particularly, epilepsy. According to the invention, compounds which inhibit the activity or expression of non-receptor Fyn tyrosine kinase can prevent activation epileptic pathophysiology and provide protection from and treatment of epilepsy. Particularly preferred is the class of small molecule Fyn kinase inhibitors such as sacaratinib and its prodrugs, derivatives, analogs and the like. | 2018-06-07 |
20180153892 | COMBINATION OF AN ANTI-CD19 ANTIBODY AND A BRUTON'S TYROSINE KINASE INHIBITOR AND USES THEREOF - The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. | 2018-06-07 |